[HTML] springer.com

[HTML][HTML] Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz, M Wegner… - Cancer Immunology …, 2022 - Springer
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …
被引用次数：4 相关文章
[HTML] nih.gov

[HTML][HTML] Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz, M Wegner… - Cancer Immunology …, 2022 - ncbi.nlm.nih.gov
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.

CU Keber, M Derigs, C Schultz, M Wegner… - Cancer Immunology …, 2022 - europepmc.org
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.

CU Keber, M Derigs, C Schultz… - Cancer Immunology …, 2022 - search.ebscohost.com
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …
[PDF] academia.edu

[PDF][PDF] Cellular and soluble immune checkpoint signaling forms PD‑L1 and PD‑1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz, M Wegner… - 2022 - academia.edu
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz… - Cancer Immunology …, 2022 - search.proquest.com
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz… - Cancer Immunol …, 2022 - kups.ub.uni-koeln.de
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.

CU Keber, M Derigs, C Schultz, M Wegner… - Cancer Immunology …, 2022 - europepmc.org
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood

CU Keber, M Derigs, C Schultz… - Cancer Immunol …, 2022 - kups.ub.uni-koeln.de
Immune checkpoint blockade therapy is a treatment option of various metastatic cancer
diseases including renal cell carcinoma (RCC). Approved antibody drugs target the co …